SecBot SecBot
Biotech Drug Report Generated Jul 14, 2026

cabozantinib

KURA·Kura Oncology, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially marketed since 2012 (first approval for medullary thyroid cancer)
Why 4/10
Cabozantinib is already approved and marketed with no pending FDA decision for the drug itself. The next major binary catalyst for Exelixis is the zanzalintinib PDUFA on December 3, 2026, a separate drug. Without a pending regulatory decision for cabozantinib, the impact score is capped at 4 (commercial cash cow, no imminent binary).
Actionable Insight NEUTRAL

Cabozantinib is Exelixis's sole approved drug, generating ~$2.12B in 2025 U.S. net revenue (17% YoY growth). The stock's next catalyst is the zanzalintinib PDUFA (Dec 3, 2026), not cabozantinib. For Kura Oncology holders: Kura's darlifarnib+cabozantinib combo data (44% ORR in pretreated ccRCC) is about Kura's drug resensitizing tumors to cabozantinib, not about cabozantinib itself. Watch Exelixis for cabozantinib commercial trends and the zanzalintinib readout.

Price Chart

Loading chart...

Executive Summary

Cabozantinib (brand names Cabometyx and Cometriq) is an already-approved, commercially successful tyrosine kinase inhibitor discovered and developed by Exelixis (EXEL). It generated ~$2.12B in U.S. net product revenue in 2025 and $2.9B globally including partner sales. With five FDA-approved indications across medullary thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer, and neuroendocrine tumors, it is Exelixis's sole marketed drug and the economic engine of the company. The filing hint pointed to Kura Oncology, Kura is studying cabozantinib in combination with their own pipeline drug darlifarnib (KO-2806) in the FIT-001 trial for kidney cancer, but does not own or develop cabozantinib. With no pending regulatory decision for cabozantinib itself, the stock's next binary catalyst is zanzalintinib's PDUFA on December 3, 2026.

How It Works

Cabozantinib is a small-molecule pill that blocks multiple signaling pathways cancers use to grow and spread, it inhibits 'tyrosine kinases' including VEGFR2 (which tumors hijack to grow blood vessels), c-MET, and AXL (which drive cancer cell growth and spread). By hitting several targets at once, it cuts off the tumor's blood supply and directly slows cancer cell growth.

Trial Status

Cabozantinib is FDA-approved for 5 indications: medullary thyroid cancer (2012, Cometriq capsules), advanced renal cell carcinoma (2016, Cabometyx tablets), hepatocellular carcinoma (2019), differentiated thyroid cancer (2021), and pancreatic/extra-pancreatic neuroendocrine tumors (March 2025). Ongoing investigator-sponsored trials continue to explore additional combinations.

The Two-Sided Case

▲ Bull Case5
Cabozantinib franchise generated ~$2.12B in U.S. net product revenue in 2025 (+17% YoY), with 2026 guidance of $2.325B–$2.425B, indicating continued commercial growth (source: Exelixis Q4/FY2025 earnings, ir.exelixis.com)
Nine consecutive years of profitability with ~$1.66B cash position and $750M stock buyback authorization, zero dilution risk for shareholders (source: biotechdistilled.substack.com analysis, Jan 2026)
New indication approvals in differentiated thyroid cancer and neuroendocrine tumors (March 2025) are expanding the addressable market (source: FDA.gov approval announcement)
Heavy institutional ownership: BlackRock (~$1.32B position), Vanguard (~$1.12B) as top holders as of Q1 2026 (source: SEC 13F filings)
Analyst consensus on EXEL is Buy (13 buy/strong-buy out of 20 ratings) with mean price target of $50.38 vs ~$56 current price, implying ~14% upside
▼ Bear Case5
Exelixis remains a single-product company economically anchored to cabozantinib, if sales erode due to competition or patent expiry, there is no other approved drug to cushion the impact (source: Wikipedia and FiercePharma Jan 2026 analysis)
Competitive pressure is intensifying in RCC and HCC from PD-1/CTLA-4 combos, HIF-2α inhibitors, and next-gen TKIs that could erode cabozantinib's market share over time (source: Strategic Market Research, kidney cancer drugs market report)
No pending binary catalyst for cabozantinib itself in the next 12 months, the next major catalyst for EXEL is zanzalintinib's PDUFA (Dec 3, 2026), a separate drug with its own binary risk (source: Exelixis Q1 2026 earnings press release)
Truist Securities downgraded EXEL from Buy to Hold in June 2026, and 11 of 20 analysts rate it Hold, not a consensus high-conviction name
Insiders have been selling under 10b5-1 plans: Director Eckhardt sold ~$492K, Director Wyszomierski sold ~$198K in June 2026 (source: SEC Form 4 filings)

Upcoming Catalysts

  • No pending FDA decision for cabozantinib itself. For Exelixis as a whole: zanzalintinib PDUFA date of December 3, 2026. For Kura Oncology's combination study: ongoing Phase 1b FIT-001 dose-optimization portion enrollment; KCRS presentation of long-term follow-up data on July 24, 2026.
  • Exelixis Q2 2026 earnings (expected late July/early August 2026) for cabozantinib sales trends.
  • Ongoing label expansion/clinical trial data presentations at medical meetings (ASCO 2026 presentations in progress).

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Kura Oncology, Inc. Press Release KURA ·Originating report

Sources · 10

Hover a chip for the title
1 en.wikipedia.org2 ir.exelixis.com3 ir.exelixis.com4 fda.gov5 ir.exelixis.com6 fiercepharma.com7 biotechdistilled.substack.com8 biospace.com9 drugs.com10 stocktitan.net